{"component": "definition", "props": {"groups": [{"size": 8, "snippet": "means the occurrence of the following event: the closing share price of the shares of Parent Common Stock over any twenty (20) consecutive Trading Days during the First Earnout Period is greater than or equal to $16.50 per share (subject to any adjustment pursuant to Section 3(c)).", "samples": [{"hash": "hQVzs0W9xVC", "uri": "/contracts/hQVzs0W9xVC#first-milestone-event", "label": "Management Earnout Agreement (Collective Audience, Inc.)", "score": 34.8507871321, "published": true}, {"hash": "2ahyQgAsDb9", "uri": "/contracts/2ahyQgAsDb9#first-milestone-event", "label": "Sponsor Earnout Agreement (Collective Audience, Inc.)", "score": 34.8507871321, "published": true}, {"hash": "bObIJ76YUL6", "uri": "/contracts/bObIJ76YUL6#first-milestone-event", "label": "Management Earnout Agreement (Abri SPAC I, Inc.)", "score": 33.8377823409, "published": true}], "snippet_links": [{"key": "shares-of-parent-common-stock", "type": "clause", "offset": [76, 105]}, {"key": "trading-days", "type": "clause", "offset": [139, 151]}, {"key": "first-earnout-period", "type": "definition", "offset": [163, 183]}, {"key": "equal-to", "type": "definition", "offset": [203, 211]}, {"key": "subject-to", "type": "definition", "offset": [230, 240]}, {"key": "pursuant-to-section", "type": "clause", "offset": [256, 275]}], "hash": "40ae932002c4d1a25b59911e28f74498", "id": 1}, {"size": 4, "snippet": "means that (a) no Event of Default shall have occurred and be continuing, and (b) Agent shall have confirmed each of the following on or prior to December 31, 2017 (which confirmation may require supporting documentation reasonably requested by Agent): (i) that Borrower has received, after June 30, 2017 but on or prior to December 31, 2017, unrestricted and unencumbered (including, not subject to any redemption, clawback, escrow or similar restriction or encumbrance) upfront net cash proceeds in a minimum amount of at least Ten Million Dollars ($10,000,000.00) in connection with the issuance and sale by Oak Street Health of its equity securities to investors reasonably acceptable to Agent (it being acknowledged and agreed that members of Oak Street Health as of the Closing Date shall be deemed reasonably acceptable to Agent), and (ii) that Borrower has achieved, with respect to any six (6) calendar month period ending after the Closing Date but on or prior to December 31, 2017, aggregate net revenue, determined in accordance with GAAP, of greater than or equal to Eighty Million Dollars ($80,000,000.00).", "samples": [{"hash": "k8XykwhCr2s", "uri": "/contracts/k8XykwhCr2s#first-milestone-event", "label": "Loan and Security Agreement (Oak Street Health, Inc.)", "score": 31.5215605749, "published": true}, {"hash": "7k8vKxYir18", "uri": "/contracts/7k8vKxYir18#first-milestone-event", "label": "Loan and Security Agreement (Oak Street Health, Inc.)", "score": 31.5215605749, "published": true}, {"hash": "8W5HnrDUASN", "uri": "/contracts/8W5HnrDUASN#first-milestone-event", "label": "Loan and Security Agreement (Oak Street Health, Inc.)", "score": 30.839835729, "published": true}], "snippet_links": [{"key": "default-shall", "type": "definition", "offset": [27, 40]}, {"key": "agent-shall", "type": "definition", "offset": [82, 93]}, {"key": "prior-to-december", "type": "clause", "offset": [137, 154]}, {"key": "supporting-documentation", "type": "definition", "offset": [196, 220]}, {"key": "by-agent", "type": "clause", "offset": [242, 250]}, {"key": "after-june", "type": "clause", "offset": [285, 295]}, {"key": "subject-to", "type": "definition", "offset": [389, 399]}, {"key": "net-cash-proceeds", "type": "definition", "offset": [480, 497]}, {"key": "minimum-amount", "type": "clause", "offset": [503, 517]}, {"key": "in-connection-with", "type": "clause", "offset": [567, 585]}, {"key": "the-issuance-and-sale", "type": "clause", "offset": [586, 607]}, {"key": "oak-street", "type": "definition", "offset": [611, 621]}, {"key": "equity-securities", "type": "clause", "offset": [636, 653]}, {"key": "agreed-that", "type": "clause", "offset": [725, 736]}, {"key": "members-of", "type": "clause", "offset": [737, 747]}, {"key": "as-of-the-closing-date", "type": "clause", "offset": [766, 788]}, {"key": "with-respect-to", "type": "clause", "offset": [875, 890]}, {"key": "calendar-month", "type": "definition", "offset": [903, 917]}, {"key": "period-ending", "type": "definition", "offset": [918, 931]}, {"key": "after-the-closing-date", "type": "clause", "offset": [932, 954]}, {"key": "net-revenue", "type": "clause", "offset": [1003, 1014]}, {"key": "in-accordance-with", "type": "definition", "offset": [1027, 1045]}, {"key": "equal-to", "type": "definition", "offset": [1071, 1079]}], "hash": "ab5ae83c0ee0afc436f85c4b0c66de5d", "id": 2}, {"size": 3, "snippet": "is receipt by Bank of evidence, satisfactory to Bank in its sole and absolute discretion, that Borrower has entered into a binding contract with Xtera to fulfill an order for one hundred (100) units, pursuant to which Borrower has received commitment fees in an amount of at least Eight Hundred Thousand Dollars ($800,000).", "samples": [{"hash": "8mfYPVhW3nW", "uri": "/contracts/8mfYPVhW3nW#first-milestone-event", "label": "Loan and Security Agreement (Acacia Communications, Inc.)", "score": 27.1464750171, "published": true}, {"hash": "3mgWBogwtxe", "uri": "/contracts/3mgWBogwtxe#first-milestone-event", "label": "Loan and Security Agreement (Acacia Communications, Inc.)", "score": 26.9685147159, "published": true}, {"hash": "aBOxbjznZMv", "uri": "/contracts/aBOxbjznZMv#first-milestone-event", "label": "Loan and Security Agreement (Acacia Communications, Inc.)", "score": 26.6509240246, "published": true}], "snippet_links": [{"key": "bank-of", "type": "clause", "offset": [14, 21]}, {"key": "to-bank", "type": "definition", "offset": [45, 52]}, {"key": "sole-and-absolute-discretion", "type": "definition", "offset": [60, 88]}, {"key": "entered-into", "type": "clause", "offset": [108, 120]}, {"key": "binding-contract", "type": "clause", "offset": [123, 139]}, {"key": "an-order", "type": "clause", "offset": [162, 170]}, {"key": "pursuant-to", "type": "definition", "offset": [200, 211]}, {"key": "commitment-fees", "type": "definition", "offset": [240, 255]}], "hash": "33ada3ba64d103bd8ae78eb57f9a1901", "id": 3}, {"size": 3, "snippet": "means confirmation by Agent that Borrower has received, after July 21, 2014, but on or prior to October 15, 2014, unrestricted and unencumbered gross cash proceeds in an amount of equal to or greater than Fifteen Million Dollars ($15,000,000) from the issuance and sale by Borrower of its equity securities and/or Subordinated Indebtedness in a transaction or a series of transactions in each case with Borrower\u2019s existing investors and investors reasonably acceptable to Agent.", "samples": [{"hash": "ks5BW2AQtR1", "uri": "/contracts/ks5BW2AQtR1#first-milestone-event", "label": "Loan and Security Agreement (Edge Therapeutics, Inc.)", "score": 26.6153319644, "published": true}, {"hash": "2j8K60p8Sdg", "uri": "/contracts/2j8K60p8Sdg#first-milestone-event", "label": "Loan and Security Agreement (Edge Therapeutics, Inc.)", "score": 25.6899383984, "published": true}], "snippet_links": [{"key": "by-agent", "type": "clause", "offset": [19, 27]}, {"key": "after-july", "type": "clause", "offset": [56, 66]}, {"key": "prior-to", "type": "clause", "offset": [87, 95]}, {"key": "gross-cash-proceeds", "type": "definition", "offset": [144, 163]}, {"key": "equal-to", "type": "definition", "offset": [180, 188]}, {"key": "the-issuance-and-sale", "type": "clause", "offset": [248, 269]}, {"key": "by-borrower", "type": "clause", "offset": [270, 281]}, {"key": "equity-securities", "type": "clause", "offset": [289, 306]}, {"key": "subordinated-indebtedness", "type": "clause", "offset": [314, 339]}, {"key": "each-case", "type": "definition", "offset": [388, 397]}, {"key": "existing-investors", "type": "definition", "offset": [414, 432]}], "hash": "1b3bc49143f67fdaa4a9731c37bf9326", "id": 4}, {"size": 2, "snippet": "shall have the meaning set forth in Section 4.2 hereof.", "samples": [{"hash": "h7s40R4uo20", "uri": "/contracts/h7s40R4uo20#first-milestone-event", "label": "License and Collaboration Agreement (Myriad Genetics Inc)", "score": 21.0, "published": true}, {"hash": "ko8XEhP3HAA", "uri": "/contracts/ko8XEhP3HAA#first-milestone-event", "label": "License Agreement (Myriad Genetics Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "section-42", "type": "clause", "offset": [36, 47]}], "hash": "9045d633116cb6d1325a77a19f4dfbf2", "id": 5}, {"size": 1, "snippet": "means the achievement of the research and development milestone described as the \u201cFirst Milestone\u201d in Exhibit E.", "samples": [{"hash": "guyPtDlZ3zo", "uri": "/contracts/guyPtDlZ3zo#first-milestone-event", "label": "Securities Purchase Agreement (Abgenix Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "development-milestone", "type": "definition", "offset": [42, 63]}, {"key": "first-milestone", "type": "definition", "offset": [82, 97]}], "hash": "0186af017297a4366bc0b0c5be8ae9ca", "id": 6}, {"size": 1, "snippet": "means the dosing of the first patient at the first trial site for a Phase 2 Clinical Trial for the Initial", "samples": [{"hash": "k7OT6sNap1g", "uri": "https://investor.eagleus.com/static-files/ee44e92e-7f8c-4636-81ad-d64f338ce0b6", "label": "investor.eagleus.com", "score": 11.3148528405, "published": false}], "snippet_links": [{"key": "site-for", "type": "clause", "offset": [57, 65]}, {"key": "phase-2-clinical-trial", "type": "definition", "offset": [68, 90]}], "hash": "706848cf62cbf0f616e076d677e68e2c", "id": 7}, {"size": 1, "snippet": "means the Kalera Ordinary Shares trading on Nasdaq with a VWAP greater than or equal to $12.50 for any twenty (20) trading days within any consecutive thirty (30)-day trading period during the Milestone Period.", "samples": [{"hash": "5oNoYklTZbL", "uri": "/contracts/5oNoYklTZbL#first-milestone-event", "label": "Contingent Value Rights Agreement (Kalera Public LTD Co)", "score": 33.5065023956, "published": true}], "snippet_links": [{"key": "ordinary-shares", "type": "definition", "offset": [17, 32]}, {"key": "trading-on-nasdaq", "type": "clause", "offset": [33, 50]}, {"key": "equal-to", "type": "definition", "offset": [79, 87]}, {"key": "trading-days", "type": "clause", "offset": [115, 127]}, {"key": "trading-period", "type": "clause", "offset": [167, 181]}, {"key": "milestone-period", "type": "definition", "offset": [193, 209]}], "hash": "5b32c4ea877918222686287c45bcd72a", "id": 8}, {"size": 1, "snippet": "means the VWAP of the shares of Common Stock over any twenty (20) Trading Days within any thirty (30) Trading Day period during the Earnout Period is greater than or equal to $12.50 per share (subject to any adjustment pursuant to Section 3(e)).", "samples": [{"hash": "jMElCZJjNKJ", "uri": "/contracts/jMElCZJjNKJ#first-milestone-event", "label": "Merger Agreement (Viveon Health Acquisition Corp.)", "score": 31.0328542094, "published": true}], "snippet_links": [{"key": "shares-of-common-stock", "type": "clause", "offset": [22, 44]}, {"key": "trading-days", "type": "clause", "offset": [66, 78]}, {"key": "trading-day-period", "type": "definition", "offset": [102, 120]}, {"key": "earnout-period", "type": "clause", "offset": [132, 146]}, {"key": "equal-to", "type": "definition", "offset": [166, 174]}, {"key": "subject-to", "type": "definition", "offset": [193, 203]}, {"key": "pursuant-to-section", "type": "clause", "offset": [219, 238]}], "hash": "c478cef45733e15d9dd724e00a9704be", "id": 9}, {"size": 1, "snippet": "means the exercise of any Option by Canam;", "samples": [{"hash": "gF9zKA2obkV", "uri": "/contracts/gF9zKA2obkV#first-milestone-event", "label": "Share Purchase Agreement (Vizsla Silver Corp.)", "score": 33.0328542094, "published": true}], "snippet_links": [{"key": "exercise-of", "type": "clause", "offset": [10, 21]}], "hash": "fbb22ad23045ffd5302e1654c7ba1a64", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIeZmlyc3QtbWlsZXN0b25lLWV2ZW50IzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 30, "snippet": "means the occurrence of the following event: the closing share price of the shares of Parent Common Stock over any twenty (20) consecutive Trading Days during the First Earnout Period is greater than or equal to $16.50 per share (subject to any adjustment pursuant to Section 3(c)).", "title": "First Milestone Event", "id": "first-milestone-event", "examples": ["The <strong>First Milestone Event</strong> shall result in the Second Closing, as defined in the Stock Purchase Agreement.", "Encarta hereby acknowledges and agrees that the payment of the First Milestone Payment and execution and delivery of the Common Stock Warrant Agreement in accordance with this Section 7 shall be timely and in full satisfaction of Verastem\u2019s obligations under Sections 4.2 and 4.3 of the Verastem License Agreement solely with respect to the <strong>First Milestone Event</strong>.", "Vizsla shall use commercially reasonable efforts to achieve the <strong>First Milestone Event</strong> within two years of the Closing Date.", "In addition, Weiss shall be entitled to receive two (2) one-time only bonuses (&quot;S\u2587\u2587\u2587\u2587\u2587l Bonuses&quot;) upon the achievement of each of the <strong>First Milestone Event</strong> and the Second Milestone Event (each as defined below), in the amount of $1,000,000 and $2,000,000 (less applicable state and federal withholdings), respectively, provided that Weiss may only receive each Special Bonus if, on the date the releva\u2587\u2587 \u2587\u2587lestone Event is achieved, he is employed by the Corporation as an officer or director.", "Notwithstanding the foregoing, in the event that, within ninety (90) days of satisfaction of the <strong>First Milestone Event</strong>, Buyer has not paid the First Milestone Payment, then the First Milestone Payment shall not be payable, and Seller shall have the right, within thirty (30) days thereafter, to require Buyer to sell the Acquired Assets to Seller for consideration of $1 by giving written notice to Buyer.", "For the avoidance of doubt, if the Purchaser terminates a Research Program with respect to a Collaboration Antigen pursuant to Section 16.2, 16.3 or 16.6 of the Collaboration Agreement, no Research Antibodies with respect to that Research Program shall count towards the <strong>First Milestone Event</strong> or the Second Milestone Event, as the case may be.", "Development Program for which Editas has not exercised its Profit-Sharing Option: <strong>First Milestone Event</strong> [**] 8 [**] [**] Second Milestone Event [**] [**] [**] [**] Third Milestone Event [**] [**] [**] [**] Fourth Milestone Event [**] [**] [**] [**] Fifth Milestone Event [**] [**] [**] [**] Sixth Milestone Event [**] [**] [**] [**] Seventh Milestone Event [**] [**] [**] [**] [**].", "For the avoidance of doubt, in the event that the <strong>First Milestone Event</strong> is not achieved by December 31, 2023, the Vifor Royalties shall not be sold or otherwise assigned to the Purchaser without the mutual agreement of the Purchaser and the Seller.", "For the further avoidance of doubt, no Research Antibodies with respect to a Co-Development Antigen shall count towards the <strong>First Milestone Event</strong> or the Second Milestone Event, as the case may be.", "Additionally, upon a Change in Control, you shall also vest on 111,111 Options which are to vest on the <strong>First Milestone Event</strong> as described in Exhibit B."], "related": [["milestone-event", "Milestone Event", "Milestone Event"], ["development-milestone-event", "Development Milestone Event", "Development Milestone Event"], ["sales-milestone-event", "Sales Milestone Event", "Sales Milestone Event"], ["development-milestone", "Development Milestone", "Development Milestone"], ["milestone-date", "Milestone Date", "Milestone Date"]], "related_snippets": [], "updated": "2025-07-06T21:56:45+00:00"}, "json": true, "cursor": ""}}